Login to Your Account



Seaside Therapeutics Blazes a Trail in Fragile X

By Catherine Shaffer


Friday, June 3, 2011
Seaside Therapeutics Inc. will begin a landmark Phase III trial to evaluate the efficacy of a drug candidate against the core symptoms of Fragile X syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription